Arcutis Biotherapeutics
Stock Forecast, Prediction & Price Target
Arcutis Biotherapeutics Financial Estimates
Arcutis Biotherapeutics Revenue Estimates
Arcutis Biotherapeutics EBITDA Estimates
Arcutis Biotherapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $0 N/A | $3.68M 0% | $59.60M 1517.09% | Avg: $246.36M Low: $231.78M High: $260.33M avg. 313.31% | Avg: $399.18M Low: $375.56M High: $421.83M avg. 62.03% | Avg: $600.37M Low: $564.84M High: $634.43M avg. 50.39% | Avg: $760.7M Low: $715.68M High: $803.86M avg. 26.70% |
Net Income
% change YoY
| $-205.90M N/A | $-321.28M -56.03% | $-262.14M 18.40% | Avg: $-138.66M Low: $-101.18M High: $-72.07M avg. 47.10% | Avg: $-8.4M Low: $-33.26M High: $18.71M avg. 93.94% | Avg: $99.10M Low: $91.48M High: $106.41M avg. 1279.84% | Avg: $172.57M Low: $159.29M High: $185.29M avg. 74.12% |
EBITDA
% change YoY
| $-206.52M N/A | $-295.80M -43.22% | $-227.43M 23.11% | Avg: $49.27M Low: $46.35M High: $52.06M avg. 121.66% | Avg: $79.83M Low: $75.11M High: $84.36M avg. 62.03% | Avg: $120.07M Low: $112.96M High: $126.88M avg. 50.39% | Avg: $152.13M Low: $143.13M High: $160.77M avg. 26.70% |
EPS
% change YoY
| -$4.17 N/A | -$5.84 -40.04% | -$3.78 35.27% | Avg: -$1.16 Low: -$1.46 High: -$1.04 avg. 69.25% | Avg: -$0.05 Low: -$0.48 High: $0.27 avg. 96.04% | Avg: $1.43 Low: $1.32 High: $1.54 avg. 3208.69% | Avg: $2.49 Low: $2.3 High: $2.67 avg. 74.12% |
Operating Expenses
% change YoY
| $206.52M N/A | $304.55M 47.46% | $295.72M -2.90% | Avg: $1.93B Low: $1.81B High: $2.04B avg. 553.45% | Avg: $3.13B Low: $2.94B High: $3.30B avg. 62.03% | Avg: $4.70B Low: $4.43B High: $4.97B avg. 50.39% | Avg: $5.96B Low: $5.61B High: $6.30B avg. 26.70% |
FAQ
What is Arcutis Biotherapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 373.75% in 2025-2028.
We have gathered data from 4 analysts. Their low estimate is -101.18M, average is -138.66M and high is -72.07M.
What is Arcutis Biotherapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 113.11% in 2025-2028.
We have gathered data from 5 analysts. Their low revenue estimate is $231.78M, average is $246.36M and high is $260.33M.
What is Arcutis Biotherapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 862.03% in 2025-2028.
We have gathered data from 4 analysts. Their low earnings per share estimate is -$1.46, average is -$1.16 and high is $-1.04.
What is the best performing analyst?
In the last twelve months analysts have been covering Arcutis Biotherapeutics stock. The most successful analyst is Uy Ear.